Clinical study on the Cancer Institute of New Jersey studies combination of steroid and experimental treat prostate cancer drug

Current article ratings:
Patients / public:healthcare Prof:5 (1 votes)
Investigators at the Cancer Institute of New Jersey started just a new clinical study that explores the impact of a new type of hormone therapy for the treatment of certain cancers that have spread beyond the prostate. CINJ is a centre of excellence of UMDNJ-Robert Wood Johnson medical school and New Jersey of only NationalCancer Institute designated Comprehensive Cancer Center-an of only 40 in the country.

Therapy, production of testosterone by the testes, is the standard first-line treatment for advanced prostate cancer to stop injections (chemical castration) treatment either by removing the testicles (surgical castration) or the type of hormone. Most patients respond to this therapy for a period of time, but ultimately their cancer cells begin to grow in spite of these measures, i.e. their cancer "Castration resistant." Often, these patients have limited treatment options.

Abiraterone acetate is an investigational drug that blocks the production of all remaining testosterone, or grow similar hormones in the body, which may help prostate cancer. Provisional data show that previously with chemotherapy docetaxel treated men drugs, who then receive lived Abiraterone more as compared to men who have not Abiraterone to docetaxel. Some of the side effects of Abiraterone, including the legs and change in the levels of some chemicals in the blood, reduce swelling is given Abiraterone with prednisone. Prednisone is one of the people caused hormone categorized as a steroid.

"Abiraterone is an exciting new approach in the field of prostate cancer, this leads us to the question what defines castration and acid-resistant cancer." Even some men who have tumors that no longer respond to hormone therapy seem a benefit from this drug. With this drug in our fight against prostate cancer there is a big step forward, said lead researcher Tina Mayer, MD, medical oncologist at the CINJ and Assistant Professor of medicine at UMDNJ-Robert Wood Johnson medical school.

Adults have been diagnosed with castration resistant prostate cancer treated with taxane-based chemotherapy and whose cancer is worsening are entitled to participate in the study even though other criteria must be met. Prior to the start in the study, participants would be required, a series of tests, including blood work and are subjected to a physical.

If accepted for participation in the study, Abiraterone acetate and prednisone would take individuals through the mouth every day over a period of 28 days. Participants would be required, to have regular scheduled check ups and would undergo laboratory reviews throughout the study.

The study is sponsored by Ortho Biotech Oncology Research & development. Dr. Mayer is paid to carry out the study of the study sponsor.

Clinical trials, often as a cancer research studies of that test new treatments and new ways of using existing therapies for cancer. In CINJ, the researchers use these studies to answer questions on the impact of a treatment of the human body and to ensure that it is safe and effective. There are several types of clinical trials to diagnose that the currently underway at CINJ, including those to treat, prevent and manage symptoms of cancer. Many treatments is used today on whether these drugs or vaccines are; Ways to do surgery or radiation therapy to give; or combinations of treatments, are the results of the recent clinical studies.

When New Jersey offers only National Cancer Institute-designated Comprehensive Cancer Center CINJ patients access to treatment in other institutions within the State that is not available. CINJ has more than 2,000 patients in clinical trials, including about 15 percent of all new adult cancer patients and about 70 percent of all pediatric cancer patients. Registration in these studies is less than five percent of all adult cancer patients nationwide.

Source:
The Cancer Institute of New Jersey